title: [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
abstract: OBJECTIVE
  To demonstrate the pharmacokinetic profile of meropenem when administered by 3-hour infusion in patients undergoing continuous veno-venous hemofiltration (CVVH).
  
  
  METHODS
  The study was conducted in 10 patients, who were treated with CVVH. Each subject received meropenem in 3-hour infusion of 500 mg every 6 hours. Blood samples were collected before infusion (0 hour) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours (just before the infusion of the next dose) after the beginning of the fourth infusion. The concentrations of meropenem in plasma were measured by high-performance liquid chromatography method, and mean serum meropenem concentration-time curve was plotted.
  
  
  RESULTS
  Peak plasma drug concentrations measured 3 hours post-infusion were (25.05 ± 5.64) mg/L, and trough levels after 6 hours of infusion were (13.03 ± 3.01) mg/L. The area under the plasma concentration-time curve (AUC) was (118.42 ± 26.78) mg x h⁻¹ x L⁻². The elimination half-life (T1/2) was (3.74 ± 0.55) hours. The mean residence time (MRT) was (4.99 ± 0.84) hours. The volume of distribution (Vb) was (22.85 ± 9.85) L and clearance of meropenem (CL) was (4.49 ± 1.32) L/h. The percentage of time that the serum drug concentration was above the minimum inhibitory concentration (MIC) accounting for the interval time of infusion (%T>MIC) was 100% (MIC 8 mg/L) in all the 10 patients.
  
  
  CONCLUSIONS
  Based on these data, we concluded that satisfactory pharmacodynamic parameters could be attained in CVVH patients treated with meropenem by a prolonged infusion time of 3 hours with a dosage of 500 mg for every 6 hours.
authors.affiliation: Beijing University Third Hospital, Beijing 100083, China.
authors.forename: Shi-ning
authors.initials: SN
authors.lastname: Bo
authors.forename: Hong-liang
authors.initials: HL
authors.lastname: Li
authors.forename: Xi
authors.initials: X
authors.lastname: Zhu
authors.forename: Gai-qi
authors.initials: GQ
authors.lastname: Yao
authors.forename: Yong-fang
authors.initials: YF
authors.lastname: Hu
authors.forename: Suo-di
authors.initials: SD
authors.lastname: Zhai
authors.forename: Wei
authors.initials: W
authors.lastname: Lu
authors.forename: Si-yuan
authors.initials: SY
authors.lastname: Wang
authors.forename: Yi-zhuang
authors.initials: YZ
authors.lastname: Xu
authors.forename: Bei
authors.initials: B
authors.lastname: He
mesh_terms: D058186:Acute Kidney Injury / Q000378:metabolism / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D005260:Female; D006440:Hemofiltration; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D000077731:Meropenem; D008875:Middle Aged; D011446:Prospective Studies; D018805:Sepsis / Q000378:metabolism / Q000628:therapy; D013845:Thienamycins / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D013845:Thienamycins; D000077731:Meropenem